Biotec Pharmacon realigns strategy and reduces workforce
Published 11.12.2009
Biotec Pharmacon has decided to reduce the workforce within the parent company by 20 people out of a total of 35, to reflect a reduced activity level following the negative outcome...
Phase III results with SBG for diabetic foot ulcer not positive
Published 23.11.2009
Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies fail...
Databases locked in both the phase III clinical studies with SBG for diabetic foot ulcer
Published 03.11.2009
Biotec Pharmacon is pleased to inform that all data management procedures have been completed, and that the databases have been locked in both of the company’s phase III studies wi...
Presenting at Bio Investor Forum in San Francisco and at Bio Europe 2009 in Vienna
Published 28.10.2009
Biotec Pharmacon has been invited to present at the 8th Annual Bio Investor Forum in San Francisco on October 28th and at BIO-Europe 2009 Conference in Vienna on November 3rd, 2009...
Presenting at Life Science Conference in New York and at Bio-Business Seminar in Zürich
Published 18.09.2009
Biotec Pharmacon has been invited to present at UBS Investment Bank’s Global Life Science Conference in New York on September 23rd and at the 5th Swiss-Scandinavian Bio-Business Se...
Biotec Pharmacon at both Biotech in Europe and BioPharm America in September
Published 11.09.2009
Biotec Pharmacon has been invited to present at Sachs Associates 9th Annual Biotech in Europe Investor Forum in Zürich on 14-15 September and on BioPharm America in San Francisco o...
Completed patient inclusion in phase III study for oral mucositis
Published 07.09.2009
Biotec Pharmacon has included 130 patients and reached the planned number of patients in its phase III study with SBG for prevention and treatment of oral mucositis. The study resu...
Biotec Pharmacon presents its cancer program at ECCP in Toulouse
Published 03.09.2009
Biotec Pharmacon on 4 September presents its clinical program with SBG for cancer at the ECCP conference, a joint meeting between Oslo Cancer Cluster and Toulouse Cancer-Bio-Sante ...
